VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.

Retinopathy of prematurity (ROP) is one of the most common causes of severe visual impairment and blindness in children worldwide. Because the blood vessels in the retina are not fully developed, ...

Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...

Obstructive sleep apnea (OSA) was associated with a notably higher risk of developing retinal vein occlusion across different demographic groups, with the greatest increase observed in people of ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...

A vascular 'fingerprint' on the light sensitive tissue layer at the back of the eye-the retina-can predict a person's risk of stroke as accurately as traditional risk factors alone, but without the ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

The use of sildenafil is associated with an increased risk for serous retinal detachment in men with erectile dysfunction, a ...